Imspex Diagnostics Ltd. news
Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions that improve monitoring and control during the manufacturing process of cell and gene therapy materials. We are lookin
The Imspex Group’s proprietary gas chromatography-ion mobility spectrometry (GC-IMS) technology was part of a ground-breaking cancer detection study that was recently carried out by a team of researchers from the University of Warwick, Coventry University and the University of Leicester. In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds (VOCs) in urine could feasibly be used to identify hepatocellular carcinoma (HCC). These findings are
Imspex Diagnostics’ patent portfolio recently grew, with news that the European Patent Office has granted the patent “Method for measuring human exhaled air”. This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory conditions. We are pleased to be able to extend use of this technology from its roots in industrial and en
A rapid and non-invasive test that can identify whether COVID-19 is present or not can make all the difference in giving people peace of mind to attend appointments for existing medical conditions or to get going again with business, education and sporting activities. This is one of the driving factors for the work of Dr Renelle Myers and her @bccancerfdn team in their Vancouver-based breath analysis study where they are using the #BreathSpec® device. Breath analysis looks to hold much pr
Imspex Diagnostics’ proprietary GC-IMS analytical technology platform has built a legacy of being a versatile, accurate and robust analytical research tool in situations where compound combinations are complex and/ or concentrations are low. Much of this legacy has centred around volatile compounds in industrial and more recently environmental and food production settings.
The ultra-highly sensitive combination of gas chromatography (GC) and Ion Mobility Spectrometry (IMS) techn
Efforts to develop a quick and non-invasive breath test for the presence of COVID-19 are underway in Vancouver, British Columbia. Imspex’s BreathSpec® is one of a battery of tests that are being used by Dr Renelle Myers and her Vancouver Coastal Health team in their work to develop a breath test that identifies the possible presence of COVID-19 in people who are showing minimal symptoms of the disease.
This study extends the aims of Imspex’s work reported in the articl
The Imspex Group’s BreathSpec technology is well-placed to play a leading role in combatting antimicrobial resistance by helping healthcare practitioners to differentiate between bacterial and viral causes of respiratory infection. This would better allow the right antibiotic to be prescribed to the right patient at the right time and in the right dose , thereby helping to minimise unnecessary prescription of antibiotics.
These findings arose from a successful bid in 2019
Findings of a feasibility study into the potential for breath analysis to help doctors to differentiate between COVID-19 and other respiratory conditions were published in The Lancet on 24 October 2020. The Imspex Group’s BreathSpec instrument showed clusters of breath compounds reflecting the effects of COVID-19’s multi-system nature. Similar cluste